Compare TDOC & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TDOC | ARDX |
|---|---|---|
| Founded | 2002 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2015 | 2014 |
| Metric | TDOC | ARDX |
|---|---|---|
| Price | $8.30 | $5.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 7 |
| Target Price | $7.56 | ★ $15.14 |
| AVG Volume (30 Days) | ★ 4.3M | 3.3M |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.58 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,406,840,000.00 | $2,607,000.00 |
| Revenue This Year | $1.19 | $37.75 |
| Revenue Next Year | $1.25 | $34.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 18.41 | N/A |
| 52 Week Low | $4.40 | $3.74 |
| 52 Week High | $9.77 | $8.40 |
| Indicator | TDOC | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 67.51 | 40.40 |
| Support Level | $7.97 | $5.46 |
| Resistance Level | $9.70 | $6.29 |
| Average True Range (ATR) | 0.41 | 0.31 |
| MACD | 0.04 | 0.04 |
| Stochastic Oscillator | 95.94 | 8.59 |
Teladoc Health Inc is engaged in the provision of virtual healthcare services, connecting patients, providers, and healthcare systems through technology-enabled platforms. The company has two reportable segments: Integrated Care and BetterHelp. The Integrated Care segment provides virtual healthcare solutions, including primary care, mental health, chronic care management, and telehealth enablement services for employers, insurers, and healthcare systems, mainly on a business-to-business basis, while the BetterHelp segment offers direct-to-consumer online mental health services, including counseling and therapy delivered through digital platforms. It generates the majority of its revenue from the Integrated Care segment.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.